Natalizumab treatment is associated with peripheral sequestration of proinflammatory T cells
- 2 June 2009
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in Neurology
- Vol. 72 (22), 1922-1930
- https://doi.org/10.1212/wnl.0b013e3181a8266f
Abstract
Natalizumab is an antibody directed against integrin alpha4 that reduces disease activity in patients with multiple sclerosis (MS) by blocking migration of T and B cells into the CNS. The goal of this study was to characterize the effects of natalizumab treatment on cytokine production and expression of activation markers, costimulatory molecules, and trafficking determinants on CD4+ and CD8+ T cells. In a longitudinal study, we investigated the expression of surface makers and cytokine expression on peripheral blood lymphocytes from 28 patients with MS who started natalizumab treatment and were followed for 1 year. A mixed effects model was used to compare pretreatment to on-treatment measurements. The frequency of CD4+ T cells producing interferon-gamma, tumor necrosis factor, and interleukin (IL)-17 upon anti-CD3 stimulation increased 6 months after initiation of natalizumab treatment and remained elevated throughout the follow-up. The frequency of CD4+ T cells expressing CD25, HLA-DR, and CCR6 ex vivo was increased at one or more time points during treatment. Among CD8+ T cells, the frequency of cells producing IL-2 and IL-17 after stimulation was increased during natalizumab treatment, as was the frequency of CD8+ T cells expressing CD58 and CCR5 ex vivo. The increase in the frequency of activated cells could not be replicated by in vitro exposure to natalizumab. Natalizumab treatment increases the percentage of activated leukocytes producing proinflammatory cytokines in blood, presumably due to sequestration of activated cells in the peripheral circulation.Keywords
This publication has 39 references indexed in Scilit:
- Randomized multicenter trial of natalizumab in acute MS relapsesNeurology, 2004
- Differential effects of treatment with a small-molecule VLA-4 antagonist before and after onset of relapsing EAEBlood, 2003
- A Controlled Trial of Natalizumab for Relapsing Multiple SclerosisThe New England Journal of Medicine, 2003
- Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitisNature Medicine, 2002
- CD4+CD25high Regulatory Cells in Human Peripheral BloodThe Journal of Immunology, 2001
- Discordant effects of anti–VLA-4 treatment before and after onset of relapsing experimental autoimmune encephalomyelitisJCI Insight, 2001
- An Interleukin-4-Induced Transcription Factor: IL-4 StatScience, 1994
- Surface expression of alpha 4 integrin by CD4 T cells is required for their entry into brain parenchyma.The Journal of Experimental Medicine, 1993
- Prevention of experimental autoimmune encephalomyelitis by antibodies against α4βl integrinNature, 1992
- The T lymphocyte glycoprotein CD2 binds the cell surface ligand LFA-3Nature, 1987